Abstract:Inhibitors of apoptosis proteins (IAPs) have been associated with tumor development and progression by affecting apoptosis through cell death signaling pathways. To date, eight IAPs (BIRC1–8) have been identified in mammalian cells. However, the role of IAPs in non–small cell lung cancer (NSCLC) development and progression has not been explored in depth. In this study, we used public datasets and bioinformatics tools to compare the expression, prognostic significance, and function of IAPs in NSCLC and its subtypes. Expression of IAPs in cancer and normal tissues and at different stages of NSCLC was compared with gene expression profiling interactive analysis, and their prognostic significance was analyzed with the Kaplan–Meier Plotter database. The correlations among IAPs were analyzed with the STRING database and SPSS19.0. Functional annotation of IAPs was analyzed by Gene Ontology and Kyoto Encyclopedia of Genes and Genomes enrichment on the basis of the DAVID tool. Among patients with lung adenocarcinoma (LUAD), the expression level of BIRC5 was higher than that in normal samples, and the expression of BIRC1 and BIRC5 significantly varied in different stages. Moreover, the BIRC1 – 3 and BIRC5 mRNA levels were associated with overall survival (OS), and the BIRC1 – 2 and BIRC5 – 6 mRNA levels were associated with progression-free survival (PFS). Among patients with lung squamous cell carcinoma (LUSC), the expression level of BIRC1 was lower and that of BIRC5 was higher than those in normal tissues, and BIRC5 expression significantly varied in different stages. BIRC1 expression was associated with OS, whereas BIRC2 and BIRC6 expression was associated with PFS. Enrichment analysis showed that most IAPs are associated with ubiquitin- and apoptosis-related pathways. Collectively, this study suggests BIRC5 as a potential diagnostic and staging marker, BIRC1 as a potential marker of OS, and BIRC2 and BIRC6 as potential PFS markers for patients with NSCLC. These highlight new targets for the early detection, treatment, and management of NSCLC.

Expression and Clinical Significance of BIRC6 in Human Epithelial Ovarian Cancer

Performing Data Mining to Explain the Correlation between the BIRC5 Gene and Prognosis in Breast Cancer Patients

Overexpression of BIRC6 Is a Predictor of Prognosis for Colorectal Cancer.

Integrated Bioinformatics Analysis and Clinical Validation Reveals That High Expression of Mucin 1 in Intrahepatic Cholangiocarcinoma Predicts Recurrence after Curative Resection.

Clinical Significance and Prognostic Value of Extracellular Signal-Regulated Kinases in Epithelial Ovarian Cancer

Expression of Orphan GPR56 Correlates with Tumor Progression in Human Epithelial Ovarian Cancer.

Expression of EphB6 in Ovarian Serous Carcinoma is Associated with Grade, TNM Stage and Survival.

[Expression and Clinical Significance of DNAJB11 in Epithelial Ovarian Cancer].

Increased ERCC1 Protein Expression is Associated with Suboptimal Debulking in Advanced Epithelial Ovarian Cancer.

BIRC5 is a prognostic biomarker associated with tumor immune cell infiltration

BIRC5 promotes cancer progression and predicts prognosis in laryngeal squamous cell carcinoma

BCL6 is a Negative Prognostic Factor and Exhibits Pro-Oncogenic Activity in Ovarian Cancer.

Overexpression of the epithelial cell adhesion molecule is associated with a more favorable prognosis and response to platinum-based chemotherapy in ovarian cancer

Eukaryotic Initiation Factor 3B is Overexpressed and Correlates with Larger Tumor Size, Advanced FIGO Stage, and Shorter Overall Survival in Epithelial Ovarian Cancer Patients.

BIRC6 Promotes Hepatocellular Carcinogenesis: Interaction of BIRC6 with P53 Facilitating P53 Degradation

Identification of prognostic markers for hepatocellular carcinoma based on the epithelial-mesenchymal transition-related gene BIRC5

The Early Diagnostic and Prognostic Value of BIRC5 in Clear-Cell Renal Cell Carcinoma Based on the Cancer Genome Atlas Data

Expression and Significance of EphB6 Protein in Colorectal Carcinoma

Correlations among ERCC1, XPB, UBE2I, EGF, TAL2 and ILF3 revealed by gene signatures of histological subtypes of patients with epithelial ovarian cancer.

ORC6 acts as a biomarker and reflects poor outcome in clear cell renal cell carcinoma

Comprehensive Analysis of Inhibitor of Apoptosis Protein Expression and Prognostic Significance in Non–Small Cell Lung Cancer